News Can Pear bud again? Ex-CEO McCann bids for assets Digital therapeutics (DTx) company Pear Therapeutics may be heading for a new lease of life, if a plan by former chief executive Corey McCann pays off.
News Neumora laid low by depression trial failure The first of three phase 3 trials of Neumora's novel antidepressant navacaprant has ended in failure, wreaking havoc with its share price.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.